A newly developed point-based staging system, the pretreatment clinical prognostic stage group system for non-metastatic prostate cancer by international staging collaboration for cancer of the prostate (STAR-CAP), including T category, N category, primary and secondary GS, pretreatment serum PSA level, percentage of positive core biopsy, and age, has been validated to outperform the NCCN 3-tier, NCCN 4-tier, and CAPRA system in predicting PCSM (28). This evidence concerns the gene KLK3 and metastatic prostate carcinoma.